A new antiviral drug, Lenacapavir, administered twice a year, has shown 100% efficacy in preventing HIV infections among young African women. The drug's success in the trial has led to recommendations for widespread accessibility in low-and-middle-income countries.
The long fight against HIV/AIDS may get a potent new weapon. A new drug, taken by injection twice a year, shows great promise in preventing new HIV infections and would ease the treatment process. https://t.co/zFZJYcMLnu
The long fight against HIV/AIDS may get a potent new weapon. A new drug, taken by injection only twice a year, shows great promise in preventing new HIV infections and would ease the treatment process since patients currently have to take daily medication. @WmBrangham has more. https://t.co/QZystUlRke
In this piece I am quoted about the overwhelming success of lenacapavir as HIV PrEP https://t.co/NyoEH3cggf
#NIAID applauds the top-line Phase 3 findings of 2x/year lenacapavir for #HIV pre-exposure prophylaxis (#PrEP) among cisgender women, a population for whom biomedical HIV prevention evidence has been limited to date. Learn more: https://t.co/Vqyuopw8Jc @GileadSciences @HIVptn https://t.co/cflkQHwmYn
“Ideally, you would have a multi-drug cocktail like we have for HIV, for instance,” https://t.co/JiHmLFloj7
Twice-yearly injections of an anti-HIV drug offered 100% protection from infection to more than 2000 cisgender adolescent girls and young women. https://t.co/hracShiJLj
Brilliant news! Zero infections in trial of ‘2 injections per year’ PrEP! It’s not a vaccine - but it’s as good, or better. This gives us the power to end new cases of HIV. Now to ensure access for all. https://t.co/wpDKR6803r
Just two injections a year of a new HIV drug protected young women in Africa from infection with the sexually transmitted disease, new trial results show. https://t.co/c0hmeLFOl6
$42,000-a-year HIV vaccine trialed in Africa The manufacturer claims the drug has a 100% prevention rate in women https://t.co/nq5gK5An3G https://t.co/ZqDiisL2nB
LENACAPAVIR (LEN): This call from activists to make this medication accessible to low-and-middle-income countries has huge relevance now that the PURPOSE 1 trial showed incredible efficacy of LEN subcutaneous every 6 months to prevent HIV (0 infections with this med in trial) https://t.co/gfUBdawrwE
This is HUGE for HIV prevention! An injection of #Lenacapavir given just twice a year demonstrated 100% efficacy for HIV prevention. An independent data monitoring committee recommended the company stop the blinded-phase trial and offer the drug to all participants. https://t.co/G8mSJ5bmBL
Big: Results from a large clinical trial in Africa showed that a twice-yearly injection of a new antiviral drug gave young women total protection from HIV https://t.co/VpgQf4WkvT
lenacaprivir $GILD, really good news New Drug Provides Total Protection From H.I.V. in Trial of Young African Women https://t.co/MZmS8pgdQA